https://www.ascopost.com/issues/june-25-2022/immunotherapy-has-given-me-back-my-life/
https://ascopost.com/issues/june-25-2022/immunotherapy-has-given-me-back-my-life/
https://www.ascopost.com/issues/june-25-2022/nivolumab-in-combination-with-chemotherapy-and-in-combination-with-ipilimumab-in-advanced-esophageal-squamous-cell-carcinoma/
https://ascopost.com/issues/june-25-2022/nivolumab-in-combination-with-chemotherapy-and-in-combination-with-ipilimumab-in-advanced-esophageal-squamous-cell-carcinoma/
https://www.ascopost.com/news/june-2022/nivolumabcabozantinib-vs-sunitinib-in-first-line-treatment-for-advanced-rcc-overall-survival-analysis-of-checkmate-9er-trial/
https://ascopost.com/news/june-2022/nivolumabcabozantinib-vs-sunitinib-in-first-line-treatment-for-advanced-rcc-overall-survival-analysis-of-checkmate-9er-trial/
https://www.ascopost.com/issues/june-25-2022/notable-trial-survival-in-pancreatic-kras-wild-type-cancer-improved-with-addition-of-nimotuzumab-to-gemcitabine/
https://ascopost.com/issues/june-25-2022/notable-trial-survival-in-pancreatic-kras-wild-type-cancer-improved-with-addition-of-nimotuzumab-to-gemcitabine/
https://www.ascopost.com/issues/june-25-2022/epov-kimmie-ng/
https://ascopost.com/issues/june-25-2022/epov-kimmie-ng/
https://www.ascopost.com/issues/june-25-2022/epov-guru-sonpavde/
https://ascopost.com/issues/june-25-2022/epov-guru-sonpavde/
https://www.ascopost.com/news/june-2022/checkmate-274-adjuvant-immunotherapy-improves-disease-free-survival-in-metastatic-urothelial-cancer/
https://ascopost.com/news/june-2022/checkmate-274-adjuvant-immunotherapy-improves-disease-free-survival-in-metastatic-urothelial-cancer/
https://www.ascopost.com/video-roundtable/updates-in-lymphoma/relapsedrefractory-hodgkin-lymphoma/
https://ascopost.com/video-roundtable/updates-in-lymphoma/relapsedrefractory-hodgkin-lymphoma/
https://www.ascopost.com/news/june-2022/three-arm-first-line-chemoimmunotherapy-study-in-patients-with-metastatic-pancreatic-cancer/
https://ascopost.com/news/june-2022/three-arm-first-line-chemoimmunotherapy-study-in-patients-with-metastatic-pancreatic-cancer/
https://www.ascopost.com/news/june-2022/neoadjuvant-immunotherapy-may-improve-survival-for-patients-with-soft-tissue-sarcoma/
https://ascopost.com/news/june-2022/neoadjuvant-immunotherapy-may-improve-survival-for-patients-with-soft-tissue-sarcoma/
https://www.ascopost.com/issues/june-3-2022-narratives-special-issue/new-fda-approved-oncology-drugs-2021-2022/
https://ascopost.com/issues/june-3-2022-narratives-special-issue/new-fda-approved-oncology-drugs-2021-2022/
https://www.ascopost.com/issues/june-10-2022/fda-approves-two-nivolumab-based-regimens-as-first-line-treatments-for-unresectable-advanced-or-metastatic-esophageal-squamous-cell-carcinoma/
https://ascopost.com/issues/june-10-2022/fda-approves-two-nivolumab-based-regimens-as-first-line-treatments-for-unresectable-advanced-or-metastatic-esophageal-squamous-cell-carcinoma/
https://www.ascopost.com/news/may-2022/neoadjuvant-nivolumab-plus-chemotherapy-in-resectable-stage-iiia-nsclc-overall-survival-and-biomarker-analyses/
https://ascopost.com/news/may-2022/neoadjuvant-nivolumab-plus-chemotherapy-in-resectable-stage-iiia-nsclc-overall-survival-and-biomarker-analyses/
https://www.ascopost.com/issues/may-25-2022/checkmate-816-neoadjuvant-nivolumab-plus-chemotherapy-improves-event-free-survival-over-chemotherapy-alone-in-resectable-nsclc/
https://ascopost.com/issues/may-25-2022/checkmate-816-neoadjuvant-nivolumab-plus-chemotherapy-improves-event-free-survival-over-chemotherapy-alone-in-resectable-nsclc/
https://www.ascopost.com/issues/may-25-2022/pd-1-inhibition-in-first-line-treatment-of-advanced-esophageal-squamous-cell-carcinoma-more-to-come-on-new-paradigm/
https://ascopost.com/issues/may-25-2022/pd-1-inhibition-in-first-line-treatment-of-advanced-esophageal-squamous-cell-carcinoma-more-to-come-on-new-paradigm/
https://www.ascopost.com/issues/may-25-2022/overall-survival-benefit-with-nivolumab-plus-chemotherapy-or-ipilimumab-vs-chemotherapy-alone-in-esophageal-squamous-cell-carcinoma/
https://ascopost.com/issues/may-25-2022/overall-survival-benefit-with-nivolumab-plus-chemotherapy-or-ipilimumab-vs-chemotherapy-alone-in-esophageal-squamous-cell-carcinoma/
https://www.ascopost.com/issues/may-25-2022/epov-edward-garon/
https://ascopost.com/issues/may-25-2022/epov-edward-garon/
https://www.ascopost.com/issues/may-25-2022/novel-neoadjuvant-therapy-may-boost-response-in-resectable-nsclc/
https://ascopost.com/issues/may-25-2022/novel-neoadjuvant-therapy-may-boost-response-in-resectable-nsclc/
https://www.ascopost.com/issues/may-25-2022/epov-mario-sznol-and-stefania-scala/
https://ascopost.com/issues/may-25-2022/epov-mario-sznol-and-stefania-scala/
https://www.ascopost.com/issues/may-25-2022/approaches-to-potentiate-immune-response-in-patients-who-do-not-respond-to-anti-pd-1-therapy-for-melanoma/
https://ascopost.com/issues/may-25-2022/approaches-to-potentiate-immune-response-in-patients-who-do-not-respond-to-anti-pd-1-therapy-for-melanoma/
https://www.ascopost.com/news/may-2022/longer-follow-up-shows-adjuvant-immunotherapy-after-bladder-cancer-surgery-may-be-associated-with-reduced-disease-recurrence/
https://ascopost.com/news/may-2022/longer-follow-up-shows-adjuvant-immunotherapy-after-bladder-cancer-surgery-may-be-associated-with-reduced-disease-recurrence/
https://www.ascopost.com/news/may-2022/anti-ctla-4-antibody-based-treatment-in-patients-with-metastatic-melanoma-experiencing-disease-progression-on-relatlimabnivolumab/
https://ascopost.com/news/may-2022/anti-ctla-4-antibody-based-treatment-in-patients-with-metastatic-melanoma-experiencing-disease-progression-on-relatlimabnivolumab/
https://www.ascopost.com/issues/june-10-2022/ipilimumabnivolumab-in-patients-with-metastatic-pancreatic-or-biliary-cancer-and-hrd-pathogenic-germline-variants/
https://ascopost.com/issues/june-10-2022/ipilimumabnivolumab-in-patients-with-metastatic-pancreatic-or-biliary-cancer-and-hrd-pathogenic-germline-variants/
https://www.ascopost.com/issues/may-10-2022/destiny-lung01-is-trastuzumab-deruxtecan-the-answer-for-her2-mutant-lung-cancer/
https://ascopost.com/issues/may-10-2022/destiny-lung01-is-trastuzumab-deruxtecan-the-answer-for-her2-mutant-lung-cancer/
https://www.ascopost.com/issues/may-10-2022/neoadjuvant-nivolumab-and-platinum-doublet-chemotherapy-for-early-nsclc/
https://ascopost.com/issues/may-10-2022/neoadjuvant-nivolumab-and-platinum-doublet-chemotherapy-for-early-nsclc/
https://www.ascopost.com/news/may-2022/nivolumab-and-salvage-nivolumabipilimumab-for-previously-untreated-advanced-clear-cell-renal-cell-carcinoma/
https://ascopost.com/news/may-2022/nivolumab-and-salvage-nivolumabipilimumab-for-previously-untreated-advanced-clear-cell-renal-cell-carcinoma/
https://www.ascopost.com/news/may-2022/sbrt-plus-nivolumab-with-or-without-ipilimumab-in-refractory-metastatic-pancreatic-cancer/
https://ascopost.com/news/may-2022/sbrt-plus-nivolumab-with-or-without-ipilimumab-in-refractory-metastatic-pancreatic-cancer/
https://www.ascopost.com/issues/may-10-2022/demystifying-immunotherapy-for-early-stage-triple-negative-breast-cancer/
https://ascopost.com/issues/may-10-2022/demystifying-immunotherapy-for-early-stage-triple-negative-breast-cancer/
https://www.ascopost.com/issues/april-25-2022/fixed-dose-nivolumab-and-relatlimab-rmbw-for-unresectable-or-metastatic-melanoma/
https://ascopost.com/issues/april-25-2022/fixed-dose-nivolumab-and-relatlimab-rmbw-for-unresectable-or-metastatic-melanoma/
https://www.ascopost.com/issues/april-25-2022/clinical-trials-updates-in-the-treatment-of-older-adults-with-gastrointestinal-malignancies/
https://ascopost.com/issues/april-25-2022/clinical-trials-updates-in-the-treatment-of-older-adults-with-gastrointestinal-malignancies/
https://www.ascopost.com/news/april-2022/checkmate-816-neoadjuvant-nivolumab-plus-chemotherapy-in-resectable-nsclc/
https://ascopost.com/news/april-2022/checkmate-816-neoadjuvant-nivolumab-plus-chemotherapy-in-resectable-nsclc/
https://www.ascopost.com/issues/april-25-2022/epov-adil-daud-and-georgina-long/
https://ascopost.com/issues/april-25-2022/epov-adil-daud-and-georgina-long/
https://www.ascopost.com/issues/april-25-2022/novel-immunotherapy-duo-delays-disease-progression-in-advanced-melanoma/
https://ascopost.com/issues/april-25-2022/novel-immunotherapy-duo-delays-disease-progression-in-advanced-melanoma/
https://www.ascopost.com/videos/aacr-annual-meeting-2022/nicolas-girard-on-nsclc-new-data-on-event-free-survival-with-nivolumab-plus-platinum-doublet-chemotherapy/
https://ascopost.com/videos/aacr-annual-meeting-2022/nicolas-girard-on-nsclc-new-data-on-event-free-survival-with-nivolumab-plus-platinum-doublet-chemotherapy/
https://www.ascopost.com/news/april-2022/biomarker-driven-assessment-of-nivolumab-nivolumabipilimumab-and-vegfr-tyrosine-kinase-inhibitors-in-first-line-treatment-of-metastatic-clear-cell-rcc/
https://ascopost.com/news/april-2022/biomarker-driven-assessment-of-nivolumab-nivolumabipilimumab-and-vegfr-tyrosine-kinase-inhibitors-in-first-line-treatment-of-metastatic-clear-cell-rcc/
https://www.ascopost.com/news/april-2022/ipilimumab-plus-nivolumab-improves-progression-free-survival-in-advanced-melanoma/
https://ascopost.com/news/april-2022/ipilimumab-plus-nivolumab-improves-progression-free-survival-in-advanced-melanoma/
https://www.ascopost.com/news/april-2022/in-the-neoadjuvant-setting-combination-immunotherapy-with-durvalumab-is-more-effective-than-durvalumab-alone-for-early-stage-nsclc/
https://ascopost.com/news/april-2022/in-the-neoadjuvant-setting-combination-immunotherapy-with-durvalumab-is-more-effective-than-durvalumab-alone-for-early-stage-nsclc/
https://www.ascopost.com/videos/aacr-annual-meeting-2022/ari-vanderwalde-on-melanoma-new-data-on-ipilimumab-and-nivolumab/
https://ascopost.com/videos/aacr-annual-meeting-2022/ari-vanderwalde-on-melanoma-new-data-on-ipilimumab-and-nivolumab/
https://www.ascopost.com/issues/april-10-2022/deciphering-clinical-outcomes-through-molecular-profiling-the-immotion151-trial/
https://ascopost.com/issues/april-10-2022/deciphering-clinical-outcomes-through-molecular-profiling-the-immotion151-trial/
https://www.ascopost.com/issues/april-10-2022/relativity-047-relatlimab-plus-nivolumab-worthy-of-further-study-in-advanced-melanoma-and-beyond/
https://ascopost.com/issues/april-10-2022/relativity-047-relatlimab-plus-nivolumab-worthy-of-further-study-in-advanced-melanoma-and-beyond/
https://www.ascopost.com/issues/april-10-2022/addition-of-anti-lag-3-antibody-relatlimab-to-nivolumab-improves-progression-free-survival-in-previously-untreated-advanced-melanoma/
https://ascopost.com/issues/april-10-2022/addition-of-anti-lag-3-antibody-relatlimab-to-nivolumab-improves-progression-free-survival-in-previously-untreated-advanced-melanoma/
https://www.ascopost.com/issues/april-10-2022/several-studies-evaluate-agents-in-the-first-line-second-line-and-later-treatment-of-advanced-kidney-cancer/
https://ascopost.com/issues/april-10-2022/several-studies-evaluate-agents-in-the-first-line-second-line-and-later-treatment-of-advanced-kidney-cancer/
https://www.ascopost.com/news/march-2022/cabozantinib-plus-nivolumab-in-advanced-non-clear-cell-renal-cell-carcinoma/
https://ascopost.com/news/march-2022/cabozantinib-plus-nivolumab-in-advanced-non-clear-cell-renal-cell-carcinoma/
https://www.ascopost.com/news/march-2022/study-evaluates-response-based-immunotherapy-strategy-in-patients-with-advanced-urothelial-carcinoma/
https://ascopost.com/news/march-2022/study-evaluates-response-based-immunotherapy-strategy-in-patients-with-advanced-urothelial-carcinoma/
https://www.ascopost.com/issues/march-25-2022-supplement-gastrointestinal-oncology-almanac/epov-anthony-el-khoueiry/
https://ascopost.com/issues/march-25-2022-supplement-gastrointestinal-oncology-almanac/epov-anthony-el-khoueiry/
https://www.ascopost.com/issues/march-25-2022-supplement-gastrointestinal-oncology-almanac/epov-ian-chau/
https://ascopost.com/issues/march-25-2022-supplement-gastrointestinal-oncology-almanac/epov-ian-chau/
https://www.ascopost.com/issues/march-25-2022-supplement-gastrointestinal-oncology-almanac/adjuvant-nivolumab-improves-disease-free-survival-vs-placebo-in-resected-esophageal-or-gastroesophageal-junction-cancer-after-neoadjuvant-chemoradiotherapy/
https://ascopost.com/issues/march-25-2022-supplement-gastrointestinal-oncology-almanac/adjuvant-nivolumab-improves-disease-free-survival-vs-placebo-in-resected-esophageal-or-gastroesophageal-junction-cancer-after-neoadjuvant-chemoradiotherapy/
https://www.ascopost.com/issues/march-25-2022-supplement-gastrointestinal-oncology-almanac/epov-rona-yaeger/
https://ascopost.com/issues/march-25-2022-supplement-gastrointestinal-oncology-almanac/epov-rona-yaeger/
https://www.ascopost.com/issues/march-25-2022-supplement-gastrointestinal-oncology-almanac/high-response-rate-seen-with-nivolumab-added-to-encorafenib-and-cetuximab-in-braf-v600e-mutated-metastatic-colorectal-cancer/
https://ascopost.com/issues/march-25-2022-supplement-gastrointestinal-oncology-almanac/high-response-rate-seen-with-nivolumab-added-to-encorafenib-and-cetuximab-in-braf-v600e-mutated-metastatic-colorectal-cancer/
https://www.ascopost.com/issues/march-25-2022-supplement-gastrointestinal-oncology-almanac/recent-fda-approvals-in-gastrointestinal-cancer/
https://ascopost.com/issues/march-25-2022-supplement-gastrointestinal-oncology-almanac/recent-fda-approvals-in-gastrointestinal-cancer/